15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Voyager Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $8.00 to $25.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $16.50 sits 434% above the current $3.09. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.48 next quarter toward $-1.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Voyager Therapeutics Inc.
As of Jul, 2 of 2 firms rate VYGR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VYGR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.48
Range $-0.76 – $-0.26 · 9 analysts · +1% YoY
Next period, 9 analysts expect Voyager Therapeutics Inc to earn $-0.48 a share (range $-0.76 – $-0.26), versus $-0.47 a year earlier. Full-year consensus is $-1.66, growing to $-1.56 the year after.
REVENUE · NEXT QUARTER
$10.2M
Range $43.0K – $39.5M · 9 analysts · -24% YoY
Revenue is expected to reach $10.2M (range $43.0K – $39.5M), -23.6% year-over-year. Full-year consensus is $39.3M, rising to $57.2M next year.
Top analysts covering Voyager Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VYGR.
#1
Laura Chico
Wedbush · Rank #122
Hold
$7.00+126.5% to target
Overall win rate
40%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$25.00+709.1% to target
Overall win rate
35%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #232
Buy
No targeton VYGR
Overall win rate
34%
+ Follow
#4
Sumant Kulkarni
Canaccord Genuity · Rank #278
Buy
$12.00+288.3% to target
Overall win rate
39%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim
Buy
$22.00+612.0% to target
Coverage
—
+ Follow
VYGR stock forecast FAQ
What is VYGR's average 12-month price target?+
The 2 analysts with a live target average $16.50 for Voyager Therapeutics Inc over the next 12 months, ranging from a $25.00 high to a $8.00 low.
Is VYGR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VYGR?+
The Street-high target is $25.00 (HC Wainwright & Co.), and the Street-low is $8.00 (Wedbush). The average of all 2 active targets is $16.50.
How many Wall Street analysts cover VYGR?+
2 analysts have an active rating on Voyager Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering VYGR?+
Among analysts who currently cover VYGR, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #122). Their current call is Hold with a $7.00 target.
What is Voyager Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.48 per share (range $-0.76 – $-0.26) across 9 analysts. Full-year EPS is projected at $-1.66, rising to $-1.56 the following year.
How much revenue is Voyager Therapeutics Inc expected to report next quarter?+
Consensus revenue is $10.2M (range $43.0K – $39.5M). Full-year revenue is projected at $39.3M, growing to $57.2M next year.
Have analysts been upgrading or downgrading VYGR lately?+
As of Jul, 2 of 2 firms rate VYGR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VYGR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
